相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Aflunov®: a vaccine tailored for pre-pandemic and pandemic approaches against influenza
Giuseppe Del Giudice et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2013)
The history of MF59 (R) adjuvant: a phoenix that arose from the ashes
Derek T. O'Hagan et al.
EXPERT REVIEW OF VACCINES (2013)
Association between Guillain-Barre syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis
Daniel A. Salmon et al.
LANCET (2013)
Implications of narcolepsy link with swine-influenza vaccine
Kelly Morris
LANCET INFECTIOUS DISEASES (2013)
AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial
Janet E. McElhaney et al.
LANCET INFECTIOUS DISEASES (2013)
Increased childhood incidence of narcolepsy in western Sweden after H1N1 influenza vaccination
Attila Szakacs et al.
NEUROLOGY (2013)
Technology transfer of an oil-in-water vaccine-adjuvant for strengthening pandemic influenza preparedness in Indonesia
Roland Ventura et al.
VACCINE (2013)
Technology transfer of oil-in-water emulsion adjuvant manufacturing for pandemic influenza vaccine production in Romania
Christopher B. Fox et al.
VACCINE (2013)
Antigen sparing with adjuvanted inactivated polio vaccine based on Sabin strains
Janny Westdijk et al.
VACCINE (2013)
Improved CD4(+) T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: A randomized trial
Isabel Leroux-Roels et al.
VACCINE (2013)
Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis
Elizabeth Miller et al.
BMJ-BRITISH MEDICAL JOURNAL (2013)
Safety of MF59-adjuvanted A/H1N1 influenza vaccine in pregnancy: a comparative cohort study
Terho Heikkinen et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2012)
Responses of solid organ transplant recipients to the AS03-adjuvanted pandemic influenza vaccine
Claire-Anne Siegrist et al.
ANTIVIRAL THERAPY (2012)
Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients
Paul Sabbatini et al.
CLINICAL CANCER RESEARCH (2012)
Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion
Nathalie Garcon et al.
EXPERT REVIEW OF VACCINES (2012)
Aflunov®: a prepandemic influenza vaccine
Roberto Gasparini et al.
EXPERT REVIEW OF VACCINES (2012)
Risk of Guillain-Barre Syndrome Following H1N1 Influenza Vaccination in Quebec
Philippe De Wals et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Safety and Immunogenicity of Multimeric-001-a Novel Universal Influenza Vaccine
Jacob Atsmon et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2012)
AF03, an alternative squalene emulsion-based vaccine adjuvant prepared by a phase inversion temperature method
Marie-Francoise Klucker et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2012)
Increased Incidence and Clinical Picture of Childhood Narcolepsy following the 2009 H1N1 Pandemic Vaccination Campaign in Finland
Markku Partinen et al.
PLOS ONE (2012)
AS03 Adjuvanted AH1N1 Vaccine Associated with an Abrupt Increase in the Incidence of Childhood Narcolepsy in Finland
Hanna Nohynek et al.
PLOS ONE (2012)
Molecular and Cellular Response Profiles Induced by the TLR4 Agonist-Based Adjuvant Glucopyranosyl Lipid A
Stacie L. Lambert et al.
PLOS ONE (2012)
Dose-range Study of MF59-adjuvanted Versus Nonadjuvanted Monovalent A/H1N1 Pandemic Influenza Vaccine in Six- to Less Than Thirty-Six-month-old Children
Stan L. Block et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2012)
Safety and immunogenicity of a novel nanoemulsion mucosal adjuvant W805EC combined with approved seasonal influenza antigens
L. R. Stanberry et al.
VACCINE (2012)
Hepatitis B virus vaccine in chronic kidney disease: Improved immunogenicity by adjuvants? A meta-analysis of randomized trials
Fabrizio Fabrizi et al.
VACCINE (2012)
One dose of an MF59-adjuvanted pandemic A/H1N1 vaccine recruits pre-existing immune memory and induces the rapid rise of neutralizing antibodies
Elisa Faenzi et al.
VACCINE (2012)
The mechanism of action of MF59 - An innately attractive adjuvant formulation
D. T. O'Hagan et al.
VACCINE (2012)
Assessment of squalene adjuvanted and non-adjuvanted vaccines against pandemic H1N1 influenza in children 6 mo to 17 y of age
Timo Vesikari et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2012)
Phase I Safety and Immunogenicity Trial of Plasmodium vivax CS Derived Long Synthetic Peptides Adjuvanted with Montanide ISA 720 or Montanide ISA 51
Socrates Herrera et al.
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE (2011)
Narcolepsy Onset Is Seasonal and Increased following the 2009 H1N1 Pandemic in China
Fang Han et al.
ANNALS OF NEUROLOGY (2011)
Effect on Cellular and Humoral Immune Responses of the AS03 Adjuvant System in an A/H1N1/2009 Influenza Virus Vaccine Administered to Adults during Two Randomized Controlled Trials
Francois Roman et al.
CLINICAL AND VACCINE IMMUNOLOGY (2011)
Intranasal Immunization of Ferrets with Commercial Trivalent Influenza Vaccines Formulated in a Nanoemulsion-Based Adjuvant
Tarek Hamouda et al.
CLINICAL AND VACCINE IMMUNOLOGY (2011)
Effectiveness of an Adjuvanted Monovalent Vaccine Against the 2009 Pandemic Strain of Influenza A(H1N1)v, in Stockholm County, Sweden
Ake Ortqvist et al.
CLINICAL INFECTIOUS DISEASES (2011)
Outlining novel cellular adjuvant products for therapeutic vaccines against cancer
Josianne Nitcheu Tefit et al.
EXPERT REVIEW OF VACCINES (2011)
MF59 adjuvant: the best insurance against influenza strain diversity
Derek T. O'Hagan et al.
EXPERT REVIEW OF VACCINES (2011)
The RTS,S vaccine candidate for malaria
Jason A. Regules et al.
EXPERT REVIEW OF VACCINES (2011)
Recent clinical experience with vaccines using MPL- and QS-21-containing Adjuvant Systems
Nathalie Garcon et al.
EXPERT REVIEW OF VACCINES (2011)
H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy
Jean-Francois Rahier et al.
GUT (2011)
Anti-HBs antibody persistence following primary vaccination with an investigational AS02v-adjuvanted hepatitis B vaccine in patients with renal insufficiency
Murielle Surquin et al.
HUMAN VACCINES (2011)
Assessment of the safety, tolerability and kinetics of the immune response to A/H1N1v vaccine formulations with and without adjuvant in healthy pediatric subjects from 3 through 17 years of age
Adriano Arguedas et al.
HUMAN VACCINES (2011)
Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations
Angelika Banzhoff et al.
HUMAN VACCINES (2011)
Safety and Immunogenicity of a Monovalent 2009 Influenza A/H1N1v Vaccine Adjuvanted With AS03A or Unadjuvanted in HIV-Infected Adults: A Randomized, Controlled Trial
Odile Launay et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
Age-Specific Effectiveness of an Oil-in-Water Adjuvanted Pandemic (H1N1) 2009 Vaccine Against Confirmed Infection in High Risk Groups in England
Nick Andrews et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
A Trimeric, V2-Deleted HIV-1 Envelope Glycoprotein Vaccine Elicits Potent Neutralizing Antibodies but Limited Breadth of Neutralization in Human Volunteers
Paul Spearman et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
Oil-in-Water Emulsion Adjuvant with Influenza Vaccine in Young Children
Timo Vesikari et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
A Field Trial to Assess a Blood-Stage Malaria Vaccine
Mahamadou A. Thera et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Development and Characterization of Synthetic Glucopyranosyl Lipid Adjuvant System as a Vaccine Adjuvant
Rhea N. Coler et al.
PLOS ONE (2011)
Response to 2009 Pandemic Influenza A (H1N1) Vaccine in HIV-Infected Patients and the Influence of Prior Seasonal Influenza Vaccination
Darius Soonawala et al.
PLOS ONE (2011)
A Phase 1 Trial of MSP2-C1, a Blood-Stage Malaria Vaccine Containing 2 Isoforms of MSP2 Formulated with Montanide® ISA 720
James S. McCarthy et al.
PLOS ONE (2011)
Influenza A/H1N1 MF59-Adjuvanted Vaccine in Preterm and Term Children Aged 6 to 23 Months
Susanna Esposito et al.
PEDIATRICS (2011)
Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88
Anja Seubert et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Inflammasome-independent role of the apoptosis-associated speck-like protein containing CARD (ASC) in the adjuvant effect of MF59
Ali H. Ellebedy et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Explorations of clinical trials and pharmacovigilance databases of MF59®-adjuvanted influenza vaccines for associated cases of narcolepsy
Theodore F. Tsai et al.
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES (2011)
MF59 Adjuvant Enhances Diversity and Affinity of Antibody-Mediated Immune Response to Pandemic Influenza Vaccines
Surender Khurana et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
An alternative renewable source of squalene for use in emulsion adjuvants
Luis A. Brito et al.
VACCINE (2011)
Increased potency of an inactivated trivalent polio vaccine with oil-in-water emulsions
Susan L. Baldwin et al.
VACCINE (2011)
Immunological priming induced by a two-dose series of H5N1 influenza antigen, administered alone or in combination with two different formulations of AS03 adjuvant in adults: Results of a randomised single heterologous booster dose study at 15 months
George Risi et al.
VACCINE (2011)
Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity
Sandra Morel et al.
VACCINE (2011)
Antibody responses to natural influenza A/H1N1/09 disease or following immunization with adjuvanted vaccines, in immunocompetent and immunocompromised children
Sara Meier et al.
VACCINE (2011)
Trivalent and quadrivalent MF59®-adjuvanted influenza vaccine in young children: A dose- and schedule-finding study
Giovanni Della Cioppa et al.
VACCINE (2011)
Association of a polymorphism of BTN2A1 with chronic kidney disease in individuals with or without hypertension or diabetes mellitus
Tetsuro Yoshida et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2011)
Guillain-Barre syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case-control study in Europe
Jeanne Dieleman et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Evaluation of a new oil adjuvant for use in peptide-based cancer vaccination
Kanako Iseki et al.
CANCER SCIENCE (2010)
Monitoring Adverse Events of the Vaccination Campaign Against Influenza A (H1N1) in the Netherlands
Eugene P. van Puijenbroek et al.
DRUG SAFETY (2010)
MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk
Paolo Durando et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2010)
New adjuvanted vaccines in pregnancy: what is known about their safety?
Carla Herberts et al.
EXPERT REVIEW OF VACCINES (2010)
Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine
Woolf T. Walker et al.
EXPERT REVIEW OF VACCINES (2010)
MF59™ as a vaccine adjuvant: a review of safety and immunogenicity
Hana El Sahly
EXPERT REVIEW OF VACCINES (2010)
Safety and immunogenicity of an investigational adjuvanted hepatitis B vaccine (HB-AS02V) in healthy adults
Jiri Beran et al.
HUMAN VACCINES (2010)
Protective effect of single-dose adjuvanted pandemic influenza vaccine in children
P. G. Van Buynder et al.
INFLUENZA AND OTHER RESPIRATORY VIRUSES (2010)
Vaccinate before the next pandemic?
Klaus Stoehr
NATURE (2010)
Safety and Immunogenicity of an AMA1 Malaria Vaccine in Malian Children: Results of a Phase 1 Randomized Controlled Trial
Mahamadou A. Thera et al.
PLOS ONE (2010)
Immunization with Cocktail of HIV-Derived Peptides in Montanide ISA-51 Is Immunogenic, but Causes Sterile Abscesses and Unacceptable Reactogenicity
Barney S. Graham et al.
PLOS ONE (2010)
Stable isotope ratios of carbon and hydrogen to distinguish olive oil from shark squalene-squalane
Federica Camin et al.
RAPID COMMUNICATIONS IN MASS SPECTROMETRY (2010)
Feasibility of single-shot H5N1 influenza vaccine in ferrets, macaques and rabbits
J. G. M. Heldens et al.
VACCINE (2010)
Phase 1 safety and immunogenicity trial of the Plasmodium falciparum blood-stage malaria vaccine AMA1-C1/ISA 720 in Australian adults
Mark A. Pierce et al.
VACCINE (2010)
Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-γ/IL-2 CD4+T cells but does not protect against experimental Plasmodium falciparum infection
James F. Cummings et al.
VACCINE (2010)
Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three Adjuvant Systems
Isabel Leroux-Roels et al.
VACCINE (2010)
Priming with AS03A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: An open non-randomised extension of a double-blind randomised primary study
Isabel Leroux-Roels et al.
VACCINE (2010)
Exposure to MF59-adjuvanted influenza vaccines during pregnancy-A retrospective analysis
Theodore Tsai et al.
VACCINE (2010)
Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults
Sharon E. Frey et al.
VACCINE (2010)
Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months
Alfonso Carmona et al.
VACCINE (2010)
Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns
Martin F. Bachmann et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study
Claire S. Waddington et al.
BMJ-BRITISH MEDICAL JOURNAL (2010)
Randomized, Double-Blind, Phase 2a Trial of Falciparum Malaria Vaccines RTS,S/AS01B and RTS,S/AS02A in Malaria-Naive Adults: Safety, Efficacy, and Immunologic Associates of Protection
Kent E. Kester et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
Squalene Emulsions for Parenteral Vaccine and Drug Delivery
Christopher B. Fox
MOLECULES (2009)
Vaccine Prevention of Maternal Cytomegalovirus Infection
Robert F. Pass et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Phase 1/2a Study of the Malaria Vaccine Candidate Apical Membrane Antigen-1 (AMA-1) Administered in Adjuvant System AS01B or AS02A
Michele D. Spring et al.
PLOS ONE (2009)
Randomized Controlled Trial of RTS,S/AS02D and RTS,S/AS01E Malaria Candidate Vaccines Given According to Different Schedules in Ghanaian Children
Seth Owusu-Agyei et al.
PLOS ONE (2009)
Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine
Grazia Galli et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels
Grazia Galli et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
MF59®-adjuvanted influenza vaccine (FLUAD®) in children: Safety and immunogenicity following a second year seasonal vaccination
T. Vesikari et al.
VACCINE (2009)
MF59-adjuvanted versus non-adjuvanted influenza vaccines: Integrated analysis from a large safety database
Michele Pellegrini et al.
VACCINE (2009)
Prepandemic influenza vaccine H5N1 (split virion, inactivated, adjuvanted) [Prepandrix (TM)] - A review of its use as an active immunization against influenza A subtype H5N1 virus
Natalie J. Carter et al.
BIODRUGS (2008)
Monitoring the effects of component structure and source on formulation stability and adjuvant activity of oil-in-water emulsions
Christopher B. Fox et al.
COLLOIDS AND SURFACES B-BIOINTERFACES (2008)
A vaccine manufacturer's approach to address medical needs related to seasonal and pandemic influenza viruses
Benoit Baras et al.
INFLUENZA AND OTHER RESPIRATORY VIRUSES (2008)
Adjuvant formulations possess differing efficacy in the potentiation of antibody and cell mediated responses to a human malaria vaccine under selective immune genes knockout environment
George S. Hui et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2008)
An adjuvanted, low-dose, pandemic influenza a (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults
Karin Levie et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
Safety and Immunogenicity of an AMA-1 Malaria Vaccine in Malian Adults: Results of a Phase 1 Randomized Controlled Trial
Mahamadou A. Thera et al.
PLOS ONE (2008)
Phase 1 Trial of Malaria Transmission Blocking Vaccine Candidates Pfs25 and Pvs25 Formulated with Montanide ISA 51
Yimin Wu et al.
PLOS ONE (2008)
Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine:: phase I randomised trial
Jean-Louis Bresson et al.
LANCET (2006)
Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine
JJ Treanor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Sucrose fatty acid sulphate esters as novel vaccine adjuvants: effect of the chemical composition
AG Blom et al.
VACCINE (2004)
Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-γ
PF Sun et al.
JOURNAL OF IMMUNOLOGY (2003)
Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults
DI Bernstein et al.
JOURNAL OF INFECTIOUS DISEASES (2002)
Human immunodeficiency virus type 1 (HIV-1) gp120-specific antibodies in neonates receiving an HIV-1 recombinant gp120 vaccine
EJ McFarland et al.
JOURNAL OF INFECTIOUS DISEASES (2001)
Adjuvants designed for veterinary and human vaccines
J Aucouturier et al.
VACCINE (2001)
分享论文
